Previous 10 | Next 10 |
2023-11-07 16:24:00 ET More on Ascendis Pharma Ascendis Pharma: Revenue Promise Meets Cash Flow Challenge Ascendis Pharma A/S (ASND) Q2 2023 Earnings Call Transcript Ascendis Pharma Q3 2023 Earnings Preview EMA advisors recommend many new meds at latest meeti...
European Commission decision for TransCon ™ PTH expected this month; if approved, first European Union launch planned in Germany in January 2024 TransCon PTH NDA resubmission to FDA expected before mid-November Completed enrollment in the Phase 3 A...
Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
• Third Quarter financial results and business update conference call to be held on November 7, 2023 • Resubmission of TransCon PTH NDA for adults with hypoparathyroidism expected before mid-November 2023 COPENHAGEN, Denmark, Oct. 31, 2023 (GLOBE NEWSWIRE) ...
— Clinical responses with TransCon IL-2 β⁄γ demonstrated as monotherapy or in combination with checkpoint inhibitor, including in two of three small cell lung cancer patients treated with combination therapy — TransCon IL-2 β⁄&...
Selected Mandated Lead Arranger for Lagoa Salgada Polymetallic VMS Project, Portugal On-boarding and formal engagement to be completed in coming weeks TORONTO, ON / ACCESSWIRE / October 18, 2023 / Ascendant Resources Inc. (TSX:ASND)(OTCQB:ASDRF)(FRA:2D9) ("Ascendant" or the "Company") ...
— 52-week results from the Phase 3 PaTHway Trial showed that the skeletal dynamics of adult patients with chronic hypoparathyroidism treated with TransCon PTH trended toward a new steady state closer to age-appropriate norms — Bone turnover markers trended toward the no...
– At Week 26, 81% of patients in Phase 3 PaTHway Trial with chronic post-surgical hypoparathyroidism, the most common cause of this disease, achieved independence from conventional therapy while maintaining normocalcemia following treatment with TransCon PTH – Post...
2023-09-28 11:07:29 ET More on BioMarin Pharmaceutical BioMarin: Q2 2023 Confirmed My Bullish View BioMarin: More Growth Is Coming BioMarin upgraded at BMO after FDA nod for hemophilia A therapy Seeking Alpha’s Quant Rating on BioMarin Pharmaceutical ...
News, Short Squeeze, Breakout and More Instantly...
Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon™ PTH in Canada Canada NewsWire MONTREAL , July 4, 2024 /CNW/ - Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distributio...
• Data demonstrate significant improvements in well-being and physical functioning compared to placebo in patients treated for 1 year with TransCon CNP at the pivotal 100μg/kg/week dose • Improvements could not be explained by changes in linear growth only, supporti...
2024-06-19 21:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...